Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CDK-IN-6, a pyrazolo[1,5-a]pyrimidine compound, exhibits potent anticancer activities as a CDK inhibitor[1].
产品描述 | CDK-IN-6, a pyrazolo[1,5-a]pyrimidine compound, exhibits potent anticancer activities as a CDK inhibitor[1]. |
体外活性 | Individual CDK’s, such as, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6 and CDK7, CDK8 and the like, perform distinct roles in cell cycle progression and can be classified as either G1, S, or G2M phase enzymes. Uncontrolled proliferation is a hallmark of cancer cells, and misregulation of CDK function occurs with high frequency in many important solid tumors[1]. |
分子量 | 380.49 |
分子式 | C21H28N6O |
CAS No. | 779353-02-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (131.41 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6282 mL | 13.1409 mL | 26.2819 mL | 65.7047 mL |
5 mM | 0.5256 mL | 2.6282 mL | 5.2564 mL | 13.1409 mL | |
10 mM | 0.2628 mL | 1.3141 mL | 2.6282 mL | 6.5705 mL | |
20 mM | 0.1314 mL | 0.657 mL | 1.3141 mL | 3.2852 mL | |
50 mM | 0.0526 mL | 0.2628 mL | 0.5256 mL | 1.3141 mL | |
100 mM | 0.0263 mL | 0.1314 mL | 0.2628 mL | 0.657 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CDK-IN-6 779353-02-5 CDK IN 6 CDKIN6 Inhibitor inhibitor inhibit